Rome Therapeutics
Latest round
- Series B
Last raised
- Jun 2023
Total raised
- $199M
Investors
- 14
About Rome Therapeutics
Rome Therapeutics is a biotechnology firm founded in 2020, located in Boston, US, specializing in treatments for diseases associated with the dark genome. The company has not undergone significant business pivots or changes since its inception. Founded by Benjamin Greenbaum and David Ting, the current CEO is Rosana Kapeller.ROME Therapeutics specializes in pioneering innovative treatments that target the previously underexplored regions of the human genome, referred to as the dark genome. Their core product offerings focus on the development of proprietary therapies that inhibit LINE-1 reverse transcriptase, a protein linked to various diseases including autoimmune disorders, cancer, and neurodegenerative conditions. Their lead program aims to leverage insights gained from their advanced data science platform and extensive knowledge of repeat biology to create breakthrough therapies. The company’s products are still in the preclinical stages, with promising results demonstrated in models of Parkinson’s disease and other related conditions.Information regarding the revenue structure of ROME Therapeutics is not publicly disclosed; however, the company engages in transactions through partnerships with research institutions, pharmaceutical companies, and healthcare providers. Additionally, the company explores B2B arrangements for product development and testing, potentially leading to licensing agreements once the therapies are commercialized.In June 2023, Rome Therapeutics, Inc. The company plans to launch new products targeting the dark genome and is focused on expanding its presence in North America and Europe, particularly targeting healthcare providers and research institutions.
Who invested in Rome Therapeutics
14 investors across 3 rounds
See all investors in Rome Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Rome Therapeutics
Who invested in Rome Therapeutics?
Rome Therapeutics has 14 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Rome Therapeutics raised?
Rome Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Rome Therapeutics last raise money?
Rome Therapeutics's most recent round on record is a Series B, in Jun 2023.
What does Rome Therapeutics do?
Rome Therapeutics is a biotechnology firm founded in 2020, located in Boston, US, specializing in treatments for diseases associated with the dark genome.
Where is Rome Therapeutics headquartered?
Rome Therapeutics is headquartered in Boston, US.
Which VCs invest in companies like Rome Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Rome Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Rome Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.